ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

NIH News: NTP To test Herbs for Toxicity

August 13, 1999

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010

Impeding Reagan Budget Cuts Feared By Cancer Program Advocates; DeVita Asks Parity With NIH

February 13, 1981

Arizona Cancer Center Seeks NCI Recognition As Comprehensive

May 29, 1987

“Leadership Vacuum: At NCI Allows NIH To Look At Reorganization, Varmus Says

November 4, 1994

Cooperative Group Leadership Changes: Decosse Heads CCIRC, Hoogstraten Chairmen’s Committee

July 8, 1977